Abstract: Objective To explore the application value of combined detection of tumor-associated autoantibodies in the diagnosis of colorectal cancer(CRC). Methods The serum specimens and clinical data of CRC patients(CRC group)and precancerous patients(precancerous group)treated in our hospital during May 2017 and November 2017, and the information of healthy controls(control group)were collected. The apurinic/apyrimidinic endonuclease 1(APE1), microtubule associated protein RP/EB family, member 1(MAPRE1)and New York esophageal squamous cell carcinoma 1(NY-ESO-1)autoantibodies levels were detected with enzyme-linked immunosorbent assay(ELISA). The diagnostic efficacies of three autoantibodies and traditional indicators(CEA and CA-199)were analyzed with receiver operating characteristic curve(ROC). Results There were significant differences in the levels of APE1 AAbs, MAPRE1 AAbs and NY-ESO-1 AAbs among the three groups. The area under the curve(AUC)of the 3 autoantibodies(0.772, 95%CI: 0.688-0.856; 0.794, 95%CI: 0.716-0.873; 0.854, 95%CI: 0.778-0.929)were higher than that of CA-199(0.571, 山 东 大 学 学 报 (医 学 版)57卷4期 -耿旭,等.多种肿瘤自身抗体对结直肠癌诊断的应用价值 \=-95%CI: 0.477-0.664, P<0.05). The AUC of NY-ESO-1 AAbs was higher than that of CEA(0.720, 95%CI: 0.639-0.801, P<0.05). The AUC of NY-ESO-1 AAbs + CEA(0.889, 95%CI: 0.829-0.949)was higher than that of NY-ESO-1 AAbs (P=0.03). The AUC of APE1 AAbs+NY-ESO-1 AAbs+CEA(0.927, 95%CI: 0.885-0.970)was statistically higher than that of NY-ESO-1 AAbs+CEA (P=0.04). Conclusion The combined detection of APE1 AAbs, NY-ESO-1 AAbs and CEA can significantly improve the diagnostic efficacy of colorectal cancer, and it is worth clinical application.

Key words: Colorectal cancer, Tumor-associated autoantibody, Apurinic/apyrimidinic endonuclease 1, New York esophageal squamous cell carcinoma 1, Diagnostic efficacy